Proposed Human Genome Diversity Project Still Plagued By Controversy And Questions

The effort to collect samples of DNA from diverse populations strives to overcome alleged public misunderstanding of its aims. SIDEBAR: For More Information MISINTERPRETED: "We need to show that this is just not a group of self-perpetuating insiders," says HGDP committee chairman Ken Weiss. Members of a National Research Council (NRC) panel evaluating the issues-both controversial and prosaic-surrounding the proposed Human Genome Diversity Project (HGDP) have their hands full. Conceived abou

Written byKaren Young Kreeger
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share


The effort to collect samples of DNA from diverse populations strives to overcome alleged public misunderstanding of its aims.

SIDEBAR: For More Information

Last month the 15-person NRC committee, commissioned by the National Institutes of Health and the National Science Foundation, heard testimony from the project's organizers as well as from its proponents and critics. The panel, which comprises geneticists, anthropologists, ethicists, and others, is charged with examining the scientific, ethical, legal, social, logistical, and funding issues that surround the international project.

HGDP organizers say it will provide new anthropological and biomedical information on the human species. "Identifying complex disease genes, and . . . disentangling multiple cases of disease" are some of the potential biomedical contributions expected of the project, stated Mary-Claire King, the American Cancer Society Professor at the University of Washington School of Medicine and an HGDP founder, at the NRC meeting.

HGDP has been endorsed by ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies